DATASHEET
Host:
Rabbit
Target Protein:
CD33
Immunogen Range:
261-364/364
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
945
Swiss Prot:
P20138
Source:
KLH conjugated synthetic peptide derived from human CD33
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:
Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).
PRODUCT SPECIFIC PUBLICATIONS
- Shi, Kejian, et al. "Sodium selenite alters microtubule assembly and induces apoptosis in vitro and in vivo." Journal of hematology & oncology 6.1 (2013): 1-9.Read more>>
- An, J. J., et al. "The ROS/JNK/ATF2 pathway mediates selenite-induced leukemia NB4 cell cycle arrest and apoptosis in vitro and in vivo." Cell Death & Disease 4.12 (2013): e973.Read more>>
- Yong-Fei Tang. et al. ARPC1B is a novel prognostic biomarker for kidney renal clear cell carcinoma and correlates with immune infiltration. FRONT MOL BIOSCI. 2023; 10: 1202524Read more>>
VALIDATION IMAGES
Human U937 cells probed with CD33 Polyclonal Antibody, Unconjugated (bs-2042R) at 0.2ug for 30 minutes followed by incubation with a PE Conjugated secondary (green) for 30 minutes compared to control cells (blue), secondary only (light blue) and isotype control (orange).
Lane 1: Jurkat lysates; Lane 2: Hela lysates probed with CD33 Polyclonal Antibody, Unconjugated (bs-2042R) at 1:500 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.